Taysha Gene Therapies Inc (NAS:TSHA)
$ 1.93 0.05 (2.66%) Market Cap: 395.54 Mil Enterprise Value: 290.14 Mil PE Ratio: 0 PB Ratio: 4.49 GF Score: 36/100

Q3 2024 Taysha Gene Therapies Inc Earnings Call Transcript

Nov 13, 2024 / 09:30PM GMT
Release Date Price: $2.21 (-7.53%)
Operator

Greetings and welcome to the Taser gene therapy's third quarter, 2024 earnings call at this time. All participants are in listen-only mode, a question and answer session will follow the formal presentation as a reminder, this conference is being recorded.

If anyone should require operator assistance during the call, please signal for an operator by pressing star and then zero. It is now my pleasure to introduce Hayleigh Collins, the Director and Head of Investor Relations. Thank you and you may proceed Hayleigh.

Hayleigh Collins
Taysha Gene Therapies Inc - Director, Head of Corporate Communications & Investor Relations

Thank you. Good afternoon and welcome to Taesa's third quarter, 2024 financial results and corporate update conference call. Earlier today, Taisha issued a press release announcing financial results for the third quarter ended September 30th 2024. Copy of this press release is available on the company's website and your sec filings. Joining me on today's call are Shawn Nolans CEO, this Margaron President and head of R&D and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot